A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases

A. E. Chang, Philip D Schneider, P. H. Sugarbaker, C. Simpson, M. Culnane, S. M. Steinberg

Research output: Contribution to journalArticle

526 Citations (Scopus)

Abstract

Sixty-four patients were entered into a randomized trial that evaluated intra-arterial (I.A.) versus intravenous (I.V.) 5-fluorodeoxyuridine (FUDR) for colorectal liver metastases. There was a significantly improved response rate for I.A. (62%) compared with I.V. (17%) treatment (p≤ 0.003). However, the improved response rate for patients in whom I.A. therapy was used did not translate to a significantly improved survival rate. The 2-year actuarial survival rates for the groups for which I.A. and I.V. therapy was used were 22% and 15% respectively, with the survival curves not differing significantly (p= 0.27). These results may have been due to the inclusion of patients with tumor in draining hepatic lymph nodes. The presence of tumor in hepatic lymph nodes was associated with a poorer prognosis. Analysis of a subgroup of patients with negative hepatic hymph nodes suggested an improved actuarial survival rate in patients for whom I.A. versus I.V. therapy was used (p≤0.03). The toxicity of I.A. FUDR was considerable, and side effects included chemical hepatitis (79%), biliary sclerosis (21%), peptic ulcers (17%) and gastritis/duodenitis (21%). The only major effect of toxicity of I.V. FUDR was severe diarrhea (59%). Regional I.A. FUDR allowed more drug delivery to liver tumors, which resulted in increased tumor responses when compared with use of systemic therapy. However, the small gain in survival seen in a select subgroup of patients with negative hepatic nodes appeared to be offset by the toxicity of I.A. FUDR.

Original languageEnglish (US)
Pages (from-to)685-693
Number of pages9
JournalAnnals of Surgery
Volume206
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Floxuridine
Neoplasm Metastasis
Drug Therapy
Liver
Survival Rate
Neoplasms
Therapeutics
Lymph Nodes
Duodenitis
Survival
Sclerosis
Gastritis
Peptic Ulcer
Hepatitis
Diarrhea
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. / Chang, A. E.; Schneider, Philip D; Sugarbaker, P. H.; Simpson, C.; Culnane, M.; Steinberg, S. M.

In: Annals of Surgery, Vol. 206, No. 6, 1987, p. 685-693.

Research output: Contribution to journalArticle

@article{4e1f1279ba144beebc7dbb2f1db5ffe0,
title = "A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases",
abstract = "Sixty-four patients were entered into a randomized trial that evaluated intra-arterial (I.A.) versus intravenous (I.V.) 5-fluorodeoxyuridine (FUDR) for colorectal liver metastases. There was a significantly improved response rate for I.A. (62{\%}) compared with I.V. (17{\%}) treatment (p≤ 0.003). However, the improved response rate for patients in whom I.A. therapy was used did not translate to a significantly improved survival rate. The 2-year actuarial survival rates for the groups for which I.A. and I.V. therapy was used were 22{\%} and 15{\%} respectively, with the survival curves not differing significantly (p= 0.27). These results may have been due to the inclusion of patients with tumor in draining hepatic lymph nodes. The presence of tumor in hepatic lymph nodes was associated with a poorer prognosis. Analysis of a subgroup of patients with negative hepatic hymph nodes suggested an improved actuarial survival rate in patients for whom I.A. versus I.V. therapy was used (p≤0.03). The toxicity of I.A. FUDR was considerable, and side effects included chemical hepatitis (79{\%}), biliary sclerosis (21{\%}), peptic ulcers (17{\%}) and gastritis/duodenitis (21{\%}). The only major effect of toxicity of I.V. FUDR was severe diarrhea (59{\%}). Regional I.A. FUDR allowed more drug delivery to liver tumors, which resulted in increased tumor responses when compared with use of systemic therapy. However, the small gain in survival seen in a select subgroup of patients with negative hepatic nodes appeared to be offset by the toxicity of I.A. FUDR.",
author = "Chang, {A. E.} and Schneider, {Philip D} and Sugarbaker, {P. H.} and C. Simpson and M. Culnane and Steinberg, {S. M.}",
year = "1987",
language = "English (US)",
volume = "206",
pages = "685--693",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases

AU - Chang, A. E.

AU - Schneider, Philip D

AU - Sugarbaker, P. H.

AU - Simpson, C.

AU - Culnane, M.

AU - Steinberg, S. M.

PY - 1987

Y1 - 1987

N2 - Sixty-four patients were entered into a randomized trial that evaluated intra-arterial (I.A.) versus intravenous (I.V.) 5-fluorodeoxyuridine (FUDR) for colorectal liver metastases. There was a significantly improved response rate for I.A. (62%) compared with I.V. (17%) treatment (p≤ 0.003). However, the improved response rate for patients in whom I.A. therapy was used did not translate to a significantly improved survival rate. The 2-year actuarial survival rates for the groups for which I.A. and I.V. therapy was used were 22% and 15% respectively, with the survival curves not differing significantly (p= 0.27). These results may have been due to the inclusion of patients with tumor in draining hepatic lymph nodes. The presence of tumor in hepatic lymph nodes was associated with a poorer prognosis. Analysis of a subgroup of patients with negative hepatic hymph nodes suggested an improved actuarial survival rate in patients for whom I.A. versus I.V. therapy was used (p≤0.03). The toxicity of I.A. FUDR was considerable, and side effects included chemical hepatitis (79%), biliary sclerosis (21%), peptic ulcers (17%) and gastritis/duodenitis (21%). The only major effect of toxicity of I.V. FUDR was severe diarrhea (59%). Regional I.A. FUDR allowed more drug delivery to liver tumors, which resulted in increased tumor responses when compared with use of systemic therapy. However, the small gain in survival seen in a select subgroup of patients with negative hepatic nodes appeared to be offset by the toxicity of I.A. FUDR.

AB - Sixty-four patients were entered into a randomized trial that evaluated intra-arterial (I.A.) versus intravenous (I.V.) 5-fluorodeoxyuridine (FUDR) for colorectal liver metastases. There was a significantly improved response rate for I.A. (62%) compared with I.V. (17%) treatment (p≤ 0.003). However, the improved response rate for patients in whom I.A. therapy was used did not translate to a significantly improved survival rate. The 2-year actuarial survival rates for the groups for which I.A. and I.V. therapy was used were 22% and 15% respectively, with the survival curves not differing significantly (p= 0.27). These results may have been due to the inclusion of patients with tumor in draining hepatic lymph nodes. The presence of tumor in hepatic lymph nodes was associated with a poorer prognosis. Analysis of a subgroup of patients with negative hepatic hymph nodes suggested an improved actuarial survival rate in patients for whom I.A. versus I.V. therapy was used (p≤0.03). The toxicity of I.A. FUDR was considerable, and side effects included chemical hepatitis (79%), biliary sclerosis (21%), peptic ulcers (17%) and gastritis/duodenitis (21%). The only major effect of toxicity of I.V. FUDR was severe diarrhea (59%). Regional I.A. FUDR allowed more drug delivery to liver tumors, which resulted in increased tumor responses when compared with use of systemic therapy. However, the small gain in survival seen in a select subgroup of patients with negative hepatic nodes appeared to be offset by the toxicity of I.A. FUDR.

UR - http://www.scopus.com/inward/record.url?scp=0023552654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023552654&partnerID=8YFLogxK

M3 - Article

C2 - 2961314

AN - SCOPUS:0023552654

VL - 206

SP - 685

EP - 693

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -